Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Company Overview

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company uses a genetically targeted approach intended to identify patients who may be more likely to respond to specific therapies.

Adial’s lead product candidate, AD04, is an investigational formulation of ondansetron, a selective serotonin-3 receptor antagonist. It is being developed for the treatment of alcohol use disorder, with the goal of reducing alcohol consumption and supporting abstinence in genetically selected patient populations. The company has also evaluated the potential application of its platform in other addictive disorders, including smoking cessation.

Founded in 2011, Adial Pharmaceuticals is headquartered in Charlottesville, Virginia. Its development programs are subject to clinical testing and regulatory review, and the company’s therapies are not approved for commercial use unless and until applicable regulatory requirements are satisfied. William M. Stilley has served as the company’s chief executive officer.

Key Stats

• Today's Range: $3.00 to $3.32
• 50-Day Range: $3.29 to $7.12
• 52-Week Range: $1.31 to $10.19
• Volume: 27,398 shs
• Average Volume: 197,389 shs
• Market Capitalization: $7.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.33
• Consensus Rating: Hold

Adial Pharmaceuticals Stock Analysis - MarketRank™

Adial Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Adial Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Adial Pharmaceuticals has a consensus price target of $8.33, representing about 161.3% upside from its current price of $3.19.

Amount of Analyst Coverage

Adial Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Adial Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adial Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adial Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.59% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 4.28.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently decreased by 12.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adial Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Adial Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Adial Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Adial Pharmaceuticals this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.00% of the stock of Adial Pharmaceuticals is held by insiders.

Percentage Held by Institutions

16.41% of the stock of Adial Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ADIL
• CIK: 1513525
• Web: www.adial.com
• Phone: (434) 422-9800
• Fax: N/A
• Employees: 6
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Adial Pharmaceuticals: $8.33
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: +171.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -203.87%
• Return on Assets: -512.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.63
• Quick Ratio: 5.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.75 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 2,630,000
• Free Float: 2,416,000
• Market Cap: $8.07 million
• Optionable: No Data
• Beta: 1.50